Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (221-230 of 277) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.
Seminars in Cancer Biology|October 13, 2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerMaria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Nature Medicine|June 27, 2018
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisPeter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsSherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2015
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsSherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Nature Medicine|August 24, 2018
Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisPeter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Histopathology|April 21, 2026
World Health Organization classification of tumours of the breast 6th edition 2026Cecily Quinn, Puay Hoon Tan, Kimberly H Allison, et al.
Journal of the National Cancer Institute|July 2, 2025
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancerShane R Stecklein, Miguel Martín, Guillermo Villacampa, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Pageof 28

Showing results (221-230 of 277) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.
Seminars in Cancer Biology|October 13, 2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerMaria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Nature Medicine|June 27, 2018
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisPeter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsSherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2015
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsSherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.
Nature Medicine|August 24, 2018
Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisPeter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Histopathology|April 21, 2026
World Health Organization classification of tumours of the breast 6th edition 2026Cecily Quinn, Puay Hoon Tan, Kimberly H Allison, et al.
Journal of the National Cancer Institute|July 2, 2025
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancerShane R Stecklein, Miguel Martín, Guillermo Villacampa, et al.
Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Pageof 28